Abstract Strategies for targeting adenomatous polyposis coli (APC) loss-of-function (APC-LOF) may provide an opportunity to intercept tumorigenesis in high-risk CRC patients, such as those with Familial Adenomatous Polyposis (FAP). Here, we uncovered a novel synthetic lethal dependency of APC-LOF on protein arginine methyltransferase (PRMT5).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with David
Contact David, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack